Last reviewed · How we verify
Tritanrix™-HepB/Hiberix™ Kft.
Tritanrix-HepB/Hiberix Kft. is a vaccine that protects against diphtheria, tetanus, pertussis, hepatitis B, and Hib infections.
Tritanrix-HepB/Hiberix Kft. is a vaccine that protects against diphtheria, tetanus, pertussis, hepatitis B, and Hib infections. Used for Protection against diphtheria, tetanus, pertussis, hepatitis B, and Hib infections in infants and children., Prevention of invasive Hib disease, including meningitis and sepsis, in children under 5 years old..
At a glance
| Generic name | Tritanrix™-HepB/Hiberix™ Kft. |
|---|---|
| Also known as | DTPw-HBV/Hib Kft |
| Sponsor | GlaxoSmithKline |
| Drug class | vaccine |
| Modality | Biologic |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
It works by stimulating the body's immune system to produce antibodies against these pathogens, providing long-term immunity. The vaccine contains inactivated or attenuated forms of the pathogens, which are unable to cause disease but can still trigger an immune response. This immune response helps the body to recognize and fight off future infections.
Approved indications
- Protection against diphtheria, tetanus, pertussis, hepatitis B, and Hib infections in infants and children.
- Prevention of invasive Hib disease, including meningitis and sepsis, in children under 5 years old.
Common side effects
- Injection site pain
- Fever
- Vomiting
- Diarrhea
Key clinical trials
- Immune Memory of DTPw-HBV/Hib Vaccine Following Primary Vaccination, Immuno & Reacto of a Booster Dose Given in Infants (PHASE3)
- Non-inferiority of GSK Biologicals' DTPw-HBV/Hib Compared to Two Formulations of GSK Biologicals' DTPw-HBV/Hib (PHASE3)
- Assess Immunogenicity, Reactogenicity, Safety of a Booster of GSK Biologicals DTPw-HBV/Hib Kft Compared to DTPw-HBV/Hib (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tritanrix™-HepB/Hiberix™ Kft. CI brief — competitive landscape report
- Tritanrix™-HepB/Hiberix™ Kft. updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI